title: Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
abstract: BACKGROUND
  Locally advanced breast cancer (LABC) remains a major clinical issue despite progress achieved in recent years. Herein, we present the mature results of a multimodality treatment program tailoring epirubicin (EPI), docetaxel (DOC) and gemcitabine-vinorelbine (GEV) peri-operatively in LABC.
  
  
  METHODS
  Stage III, Eastern Cooperative Oncology Group-Performance status ≤2 patients were eligible. A biopsy documentation had to be performed before the start of chemotherapy (CT). Treatment consisted of four EPI (100 mg/m(2), d1q2w) followed by three DOC (100 mg/m(2), d1q3w); surgery 3-4 weeks from CT completion, followed by radiation therapy (RT) and CT according to response; partial or complete (PR/CR):DOC, no change or progressive disease (NC/PD):GEV. Primary endpoints were: (a) response and conversion to operability/conservative surgery and (b) overall survival (OS) and time to recurrence (TTR).
  
  
  RESULTS
  Fifty-six women, aged 32-75 (median 52 years), 24 IIIA and 32 IIIB were enrolled; 53 patients completed the entire program. Toxicity was acceptable and no treatment-related death was observed.
  
  
  RESULTS
  clinical response rate (RR) 71.4% (40 patients); clinical complete response rate 33.9% (19 patients). Pathological response rate (RR) 67.8% (38 patients); pathological complete response rate 21.4% (12 patients). 33 (58.9%) and 19 (33.9%) patients, respectively, had radical and conservative operations without increased morbidity. After a median follow-up of 62 months, median OS has not yet been reached, while median TTR was 42 months. OS was longer in patients with clinical (p = 0.004) and pathological response (p = 0.002), RT (p < 0.0001) and post-operative DOC (p = 0.038). TTR was favorably affected by pR (p < 0.0001), RT (p < 0.0004) and post-operative DOC (p = 0.005). Pre-operative CT seemed to be equally active throughout all subgroups according to histology, ER/PR and HER2 status.
  
  
  CONCLUSIONS
  The treatment program of the present study allowed for the completion of an effective therapy at the cost of acceptable toxicity. The results of this study suggest a central role of CT for LABC and the value of eventually dose-dense, EPI- and DOC-based CT in a large proportion of LABC patients, regardless of biological tumor profile. Furthermore, tumor response (cR, pR) is an important surrogate for patients survival and further therapy management.
authors.affiliation: First Department of Medical Oncology, St. Savas Anticancer Hospital, 171 Alexandras' Avenue, 11522 Athens, Greece. pantkount@gmail.com
authors.forename: Panteleimon
authors.initials: P
authors.lastname: Kountourakis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Missitzis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Doufexis
authors.forename: Vassileios
authors.initials: V
authors.lastname: Zobolas
authors.forename: Georgios
authors.initials: G
authors.lastname: Pissakas
authors.forename: Niki
authors.initials: N
authors.lastname: Arnogiannaki
authors.forename: Savoula
authors.initials: S
authors.lastname: Maliou
authors.forename: Anastasia
authors.initials: A
authors.lastname: Sotiropoulou
authors.forename: Alexandros
authors.initials: A
authors.lastname: Ardavanis
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077143:Docetaxel; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D018579:Patient Selection; D018714:Radiotherapy, Adjuvant; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine
references.citation: Anticancer Res. 2007 Jul-Aug;27(4C):2989-92
references.pmid: 17695483
references.citation: J Clin Oncol. 1999 Feb;17(2):460-9
references.pmid: 10080586
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1037-44
references.pmid: 16505422
references.citation: J Clin Oncol. 1993 Jul;11(7):1245-52
references.pmid: 8315421
references.citation: J Clin Oncol. 1998 Aug;16(8):2672-85
references.pmid: 9704717
references.citation: J Clin Oncol. 1992 Jun;10(6):1014-24
references.pmid: 1588366
references.citation: Ann Oncol. 2003 Mar;14(3):406-13
references.pmid: 12598346
references.citation: J Clin Oncol. 2006 May 1;24(13):2019-27
references.pmid: 16606972
references.citation: Breast Cancer Res Treat. 2005 Apr;90(3):215-21
references.pmid: 15830134
references.citation: Oncologist. 2006 Jun;11(6):563-73
references.pmid: 16794236
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Clin Oncol. 2008 Feb 10;26(5):778-85
references.pmid: 18258986
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3628-36
references.pmid: 12202663
references.citation: J Clin Oncol. 2004 Oct 15;22(20):4067-74
references.pmid: 15483018
references.citation: J Clin Oncol. 1995 Nov;13(11):2722-30
references.pmid: 7595730
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1456-66
references.pmid: 11896092
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2676-85
references.pmid: 15837982
references.citation: J Clin Oncol. 2010 Jan 1;28(1):83-91
references.pmid: 19901111
references.citation: Oncologist. 2003;8(6):521-30
references.pmid: 14657530
references.citation: Cancer Chemother Pharmacol. 2003 Aug;52(2):147-52
references.pmid: 12764672